ASCO 2023 | ASC2ESCALATE: Phase II dose-escalation study of second-line asciminib in patients with CML-CP
Jorge Cortes
• 9 Jun 2023
Jorge Cortes, MD, Augusta University, Augusta, GA, describes the rationale and aims of the Phase II ASC2ESCALATE study (NCT05384587) evaluating the safety and efficacy of asciminib in the second-line setting with dose-escalation in patients with chronic myeloid leukemia in chronic phase (CMP-CP) who do not achieve BCR:ABL1IS ≤ 1% at 6 months.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant for Pfizer, Novartis, Takeda, Sun Pharma, Rigel and Forma Therapeutics. Dr Cortes’ institution receives research support from Pfizer, Takeda, Novartis and Sun Pharma.
